Biofrontera Inc
Change company Symbol lookup
Select an option...
BFRI Biofrontera Inc
ALTR Altair Engineering Inc
CVX Chevron Corp
ASCB ASPAC II Acquisition Corp
STRS Stratus Properties Inc
ESMC Escalon Medical Corp
ATO Atmos Energy Corp
LVS Las Vegas Sands Corp
HUBB Hubbell Inc
PM Philip Morris International Inc
Go

Company profile

Biofrontera Inc. is a biopharmaceutical company. The Company is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. It also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The Company’s other product include Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.

Closing Price
$1.05
Day's Change
0.05 (5.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.10
Day's Low
1.00
Volume
(Below Average)
Volume:
252,390

10-day average volume:
290,375
252,390
Latest Earnings Beat Consensus (Q2 ending 06/2022)Next Earnings Announcement
Q2
Announced August 12, 2022
-$0.05Q2 Consensus
of 2 analysts
-$0.34Difference from
consensus
85.29%
Q3 Earnings
will announce
(Unconfirmed) November 30, 2022

Quarterly Earnings History and Estimates

Hide high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

BFRI's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.